Markets See Risk Around Pfizer-Allergan Merger Deal

The video discusses the market's reaction to Pfizer's potential acquisition of Allergan, focusing on the Treasury's crackdown on serial inverters. It explores the implications of new Treasury rules, debates on corporate tax rates, and the business rationale behind the acquisition. The video also highlights the legal uncertainties and regulatory challenges companies face in such deals.

How might changes in tax regulations affect foreign acquisitions of U.S. companies?

What reasons might Pfizer have for wanting to acquire Allergan beyond tax benefits?

What is the significance of the uncertainty surrounding the deal for Pfizer?